US FDA Eyes Ocular Risks With GlaxoSmithKline’s Myeloma Drug Belantamab

 
• By Sue Sutter
  
close up of band keratopathy during eye examination. in dark room.
US FDA is concerned the risk of keratopathy with belantamab may outweigh the drug's benefits. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers